Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

Diabetes

Volumn 55, Issue 10, 2006, Pages 2688-2697

  Carey, Andrew L ^a,b   Steinberg, Gregory R ^b   Macaulay, S Lance ^c   Thomas, Walter G ^d   Holmes, Anna G ^a   Ramm, Georg ^e   Prelovsek, Oja ^a   Hohnen Behrens, Cordula ^e   Watt, Matthew J ^a,b   James, David E ^e   Kemp, Bruce E ^b,c   Pedersen, Bente K ^f   Febbraio, Mark A ^a,d  

^a RMIT UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CSIRO   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5' AMP ACTIVATED PROTEIN KINASE; 5'-AMP-ACTIVATED PROTEIN KINASE; AICA RIBONUCLEOTIDE; DRUG DERIVATIVE; FATTY ACID; INTERLEUKIN 6; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; RIBONUCLEOTIDE; SLC2A4 PROTEIN, RAT; SOCS3 PROTEIN, RAT; STAT3 PROTEIN, RAT; SUPPRESSOR OF CYTOKINE SIGNALING;

ADIPOCYTE; ADULT; ALPHA CHAIN; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; INSULIN RESISTANCE; LIPOLYSIS; MALE; MOUSE; MUSCLE METABOLISM; MYOTUBE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ANIMAL; CELL LINE; CELL MEMBRANE; CELL STRAIN 3T3; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; METABOLISM; MOUSE MUTANT; MYOBLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

3T3-L1 CELLS; ADULT; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; CELL LINE; CELL MEMBRANE; FATTY ACIDS; GLUCOSE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPERINSULINISM; INSULIN; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; MYOBLASTS; PROTEIN-SERINE-THREONINE KINASES; RATS; RECOMBINANT PROTEINS; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33750859187     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1404     Document Type: Article

References (45)

1. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 (Suppl. 3):S53-S55, 2003
2. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
3. Lazar M: How obesity causes diabetes: not a tall tale. Science 307:373-375, 2005
4. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067, 2004
5. Lyngsø D, Simonsen L, Bulow J: :Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 543:379-386, 2002
6. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, Pedersen BK: Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155-E162, 2005
7. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK: Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 548:631-638, 2003
8. Stouthard JM, Oude Elferink RP, Sauerwein HP: Interleukin-6 enhances glucose transport in 3T3-L1 adipocytes. Biochem Biophys Res Commun 220:241-245, 1996
9. Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Haring HU, Schleicher ED: Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 279:23942-23952, 2004
10. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED: Interleukin-6 (IL-6) acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser-473 of Akt. Am J Physiol Endocrinol Metab 289:E251-E257, 2005
11. Rotter V, Nagaev I, Smith, U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and TNFalpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45785, 2003
12. Bruce CR, Dyck DJ: Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287:E616-E621, 2004
13. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK: Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-3010, 2003
14. Shulman GI: Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology 19:183-190, 2004
15. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB: AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320:449-454, 2004
16. Kahn BB, Alquier T, Carling D, Hardie DG: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25, 2005
17. Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA: Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 282:E18-E23, 2002
18. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE: 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 276:46912-46916, 2001
19. Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK: Tumor necrosis factor- α induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 54:2939-2945, 2005
20. van Hall G, Sacchetti M, Radegran G, Saltin B: Human skeletal muscle fatty acid and glycerol metabolism during rest, exercise and recovery. J Physiol 543:1047-1058, 2002
21. Angus DJ, Hargreaves M, Dancey J, Febbraio MA: Effect of carbohydrate or carbohydrate plus medium-chain triglyceride ingestion on cycling time trial performance. J Appl Physiol 88:113-119, 2000
22. Cayphas S, Van Damme J, Vink A, Simpson RJ, Billiau A, Van Snick J: Identification of an interleukin HP1-like plasmacytoma growth factor produced by L cells in response to viral infection. J Immunol 139:2965-2969, 1987
23. Watt MJ, Dzamko N, Thomas WG, Rose-John S, Ernst M, Carling D, Kemp BE, Febbraio MA, Steinberg GR: CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541-548, 2006
24. Southgate RJ, Bruce CR, Carey AL, Steinberg GR, Walder K, Monks R, Watt MJ, Hawley JA, Birnbaum MJ, Febbraio MA: PGC-1alpha gene expression is down-regulated by Akt- mediated phosphorylation and nuclear exclusion of FoxO1 in insulin-stimulated skeletal muscle. FASEB J 19:2072-2074, 2005
25. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M, Carling D: LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13:2004-2008, 2003
26. Shewan AM, Marsh BJ, Melvin DR, Martin S, Gould GW, James DE: The cytosolic C-terminus of the glucose transporter GLUT4 contains an acidic cluster endosomal targeting motif distal to the dileucine signal. Biochem J 350:99-107, 2000
27. Govers R, Coster AC, James DE: Insulin increases cell surface GLUT4 levels by dose dependently discharging GLUT4 into a cell surface recycling pathway. Mol Cell Biol 24:6456-6466, 2004
28. Chen ZP, McConell GK, Michell BJ, Snow RJ, Canny BJ, Kemp BE: AMPK signaling in contracting human skeletal muscle: aceyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 279:E1202-E1206, 2000
29. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acutephase responses in interleukin-6-deficient mice. Nature 368:339-342, 1994
30. Baron AD, Brechtel G, Wallace P, Edelman SV: Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol Endocrinol Metab 255:E769-E774, 1988
31. Wallenius V, Wallenius K, Ahren B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79, 2002
32. Febbraio MA, Pedersen BK: Muscle derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335-1347, 2002
33. Wojtaszewski JF, Jorgensen SB, Frosig C, MacDonald C, Birk JB, Richter EA: Insulin signalling: effects of prior exercise. Acta Physiol Scand 178:321-328, 2003
34. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific Pparg deletion causes insulin resistance. Nat Med 9:1491-1497, 2003
35. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman, GI: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-608, 2005
36. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA: Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784-2789, 2003
37. Klover PJ, Clementi AH, Mooney RA: Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417-3427, 2005
38. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA: Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. Am J Physiol Cell Physiol 280:C769-C774, 2001
39. Watt MJ, Hevener A, Lancaster GI, Febbraio MA: Ciliary neurotrophic factor prevents acute lipid-induced insulin resistance by attenuating ceramide accumulation and phosphorylation of JNK in peripheral tissues. Endocrinology 147:2077-2085, 2006
40. Steinberg GR, Watt MJ, Fam BC, Proietto J, Andrikopoulos S, Allan A, Febbraio MA, Kemp BE: Ciliary neurotrophic factor suppresses hypothalamic AMPK signaling in leptin resistant obese mice. Endocrinology 147:3906-3914, 2006
41. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746, 2003
42. Ueki K, Kondo T, Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446, 2004
43. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED: Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281:7060-7067, 2006
44. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO: Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 293:560-565, 2002
45. Barnes BR, Long YC, Steiler TL, Leng Y, Galuska D, Wojtaszewski JF, Andersson L, Zierath JR: Changes in exercise-induced gene expression in 5′-AMP-activated protein kinase γ3-null and γ3 R225Q transgenic mice. Diabetes 54:3484-3489, 2005